MK-3795 is under clinical development by Merck & Co and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MK-3795’s likelihood of approval (LoA) and phase transition for Von Hippel-Lindau Syndrome took place on 28 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MK-3795 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MK-3795 overview

MK-3795 is under development for the treatment of von Hippel-Lindau disease. It was under development for the treatment of von Hippel-Lindau disease-associated advanced clear cell renal cell carcinoma as a monotherapy, in combinations with immuno-oncology and tyrosine kinase inhibitors for clear renal cell carcinoma and recurrent glioblastoma multiforme. It is a small molecule administered orally as a tablet. It acts by targeting hypoxia-inducible factor-2 alpha (HIF-2alpha).

Merck & Co overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Quick View MK-3795 LOA Data

Report Segments
  • Innovator
Drug Name
  • MK-3795
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Developers
  • Sponsor Company: Merck & Co
  • Originator: University of Texas Southwestern Medical Center
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.